Neximmune terminates equity sales agreement and ATM program

In a regulatory filing, NexImmune stated that as previously disclosed in June 2022, the company entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald and BTIG, pursuant to which the company could offer and sell shares of its common stock having an aggregate offering price of up to $50M, from time to time through an “at the market” offering program, or the “ATM Program,” and filed a prospectus supplement and the accompanying prospectus, as subsequently supplemented, relating to the ATM Program of up to $4,150,000 of shares of common stock pursuant to the sales agreement. On February 2, the company and each of the agents mutually agreed to terminate the sales agreement and the ATM Program effective immediately. The company will not incur any material early termination penalties in connection with the termination of the sales agreement and the ATM Program. Prior to termination, the company issued and sold 127,396 shares of common stock under the sales agreement, raising net proceeds of approximately $5.1M, the filing noted.